#1 Clinical Trials Search in Europe

Amy109

A new drug called AMY109 is being studied in clinical trials to treat endometriosis, a painful condition affecting women. This article explores the ongoing research into AMY109’s effectiveness and safety for managing endometriosis symptoms and its potential to improve the lives of those living with this condition.

Table of Contents

What is AMY109?

AMY109 is a new medication currently being studied for the treatment of endometriosis, a painful condition affecting many women. It is classified as an investigational drug, which means it is still undergoing clinical trials to determine its effectiveness and safety.[1]

How AMY109 Works

While the exact mechanism of AMY109 is not fully described in the available information, it is known to be a type of antibody preparation. Antibodies are proteins that can target specific substances in the body. In this case, AMY109 appears to target a substance called IL-8 (Interleukin-8), which may play a role in the development or progression of endometriosis.[1]

Target Condition: Endometriosis

Endometriosis is a condition where tissue similar to the lining of the uterus grows outside the uterus. This can cause severe pain, especially during menstruation (dysmenorrhea) and sexual intercourse (dyspareunia). It can also lead to chronic pelvic pain, known as non-menstrual pelvic pain (NMPP). AMY109 is being studied to see if it can help reduce these symptoms and improve the quality of life for women with endometriosis.[1]

Clinical Trial Details

The clinical trial for AMY109 is a Phase II study, which means it’s testing the drug’s effectiveness and safety in a larger group of people after initial safety studies have been completed. The study is described as randomized and double-blind, which are important features that help ensure the results are reliable.[1]

The main goals of the study are:

  • To evaluate how well AMY109 works compared to a drug called desogestrel
  • To assess the effectiveness of AMY109 when used in combination with desogestrel
  • To measure changes in endometriosis severity using laparoscopy (a type of minimally invasive surgery) and magnetic resonance imaging (MRI)[1]

Eligibility Criteria

To participate in the AMY109 clinical trial, patients must meet certain criteria. Some key requirements include:

  • Being a woman between 18 and 49 years old
  • Having moderate to severe endometriosis-related pain, including:
    • Non-menstrual pelvic pain (NMPP): A pain score of 4 or higher on at least 4 days during the screening period
    • Dysmenorrhea (painful periods): A pain score of 4 or higher on at least 2 days during the screening period
  • For some participants, having a confirmed diagnosis of stage III or IV endometriosis based on a previous laparoscopy
  • For others, having at least one ovarian endometrioma (a type of cyst) or endometriotic nodule visible on MRI[1]

Exclusion Criteria

Certain factors may prevent participation in the trial. These include:

  • Significant abnormalities in laboratory tests or physical examinations
  • Chronic pelvic pain not caused by endometriosis
  • Previous hysterectomy (removal of the uterus) or removal of both ovaries
  • Recent treatment with other antibody medications
  • Previous treatment with anti-IL-8 antibodies[1]

Potential Benefits

While the effectiveness of AMY109 is still being studied, the researchers hope it may offer several potential benefits for women with endometriosis:

  • Reduction in pain associated with endometriosis, including non-menstrual pelvic pain and painful periods
  • Improvement in the appearance of endometriosis lesions as seen on laparoscopy or MRI
  • Potential alternative or addition to current treatments for endometriosis[1]

Administration and Dosage

AMY109 is administered as a solution for injection through intravenous infusion. This means it’s given directly into a vein. The maximum daily dose being studied is 10 mg/kg (milligrams per kilogram of body weight), with a maximum total dose of 130 mg/kg over the course of treatment. The treatment period may last up to 52 weeks (1 year).[1]

Aspect Details
Study Type Phase II, randomized, double-blind
Drug Studied AMY109 (alone and with desogestrel)
Condition Endometriosis
Main Objective Evaluate efficacy and safety of AMY109
Primary Endpoints Changes in r-ASRM score and endometriotic nodule size
Eligibility Age 18-49 years
Key Inclusion Criteria Moderate to severe endometriosis-related pain
Study Cohorts Laparoscopy (UK), Imaging (EU)
AMY109 Administration Intravenous infusion
Maximum Treatment Period 52 weeks

FAQ

  • What is AMY109? AMY109 is a new drug being tested in clinical trials for the treatment of endometriosis. It is given as a solution for injection through intravenous infusion.
  • What is the main goal of the AMY109 clinical trial? The main goal is to evaluate how well AMY109 works, both alone and in combination with desogestrel, compared to desogestrel alone in reducing the severity of endometriosis. This is assessed through laparoscopy (in the UK) and magnetic resonance imaging (MRI).
  • Who can participate in the AMY109 clinical trial? Women aged 18-49 with moderate to severe endometriosis-related pain can participate. They must have specific pain levels during screening and be willing to switch to study-approved pain medications.
  • How is the effectiveness of AMY109 being measured? The effectiveness is measured by changes in the revised American Society of Reproductive Medicine (r-ASRM) score from before to after treatment, assessed by laparoscopy in the UK. It's also measured by changes in the size of endometriotic nodules seen on MRI scans.
  • Are there any specific requirements for participating in different parts of the study? Yes, there are two cohorts: a laparoscopy cohort (UK only) and an imaging cohort (EU only). The laparoscopy cohort requires participants to have a recent laparoscopic diagnosis and be willing to have surgery after the study. The imaging cohort requires participants to have specific findings on MRI scans.

Ongoing Clinical Trials on Amy109

  • Study on the Effectiveness and Safety of AMY109 and Desogestrel for Women with Endometriosis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Poland Romania

Glossary

  • Endometriosis: A condition where tissue similar to the lining of the uterus grows outside the uterus, causing pain and potential fertility issues.
  • AMY109: An investigational drug being studied for the treatment of endometriosis, given as an intravenous infusion.
  • Desogestrel: A type of progestin hormone used in birth control and for treating certain gynecological conditions.
  • Laparoscopy: A minimally invasive surgical procedure used to examine the organs inside the abdomen and pelvis.
  • MRI (Magnetic Resonance Imaging): A medical imaging technique that uses strong magnetic fields and radio waves to create detailed images of the body's internal structures.
  • Dysmenorrhea: Painful menstrual cramps.
  • Dyspareunia: Pain during sexual intercourse.
  • NMPP (Non-Menstrual Pelvic Pain): Pelvic pain that occurs outside of menstruation.
  • NRS (Numerical Rating Scale): A pain scale used to measure the intensity of pain, typically ranging from 0 to 10.
  • r-ASRM (revised American Society of Reproductive Medicine) score: A system used to classify the severity and extent of endometriosis based on findings during laparoscopy.
  • Endometrioma: A type of cyst formed when endometrial tissue grows in the ovaries.
  • Endometriotic nodule: A solid mass of endometrial tissue growing outside the uterus.
  • Adenomyosis: A condition where the inner lining of the uterus breaks through the muscle wall of the uterus.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-amy109-and-desogestrel-for-women-with-endometriosis/